Show simple item record

dc.contributor.authorKoupenova-Zamor, Milka
dc.contributor.authorFreedman, Jane E.
dc.date2022-08-11T08:08:09.000
dc.date.accessioned2022-08-23T15:44:36Z
dc.date.available2022-08-23T15:44:36Z
dc.date.issued2020-11-06
dc.date.submitted2020-11-25
dc.identifier.citation<p>Koupenova M, Freedman JE. Platelets and COVID-19: Inflammation, Hyperactivation and Additional Questions. Circ Res. 2020 Nov 6;127(11):1419-1421. doi: 10.1161/CIRCRESAHA.120.318218. Epub 2020 Nov 5. PMID: 33151798; PMCID: PMC7641185. <a href="https://doi.org/10.1161/CIRCRESAHA.120.318218">Link to article on publisher's site</a></p>
dc.identifier.issn0009-7330 (Linking)
dc.identifier.doi10.1161/CIRCRESAHA.120.318218
dc.identifier.pmid33151798
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27352
dc.description.abstractThe mechanisms underlining thrombosis in COVID-19 patients are not known and likely due to multiple processes including inflammation, oxygen demand injury, and plaque rupture triggered by the infection. Platelets mediate thrombotic vascular occlusion but are also increasingly recognized to have immunomodulatory activity. Several of our recent studies have characterized the role of viral infections in cardiac disease. Although robust data on the scope of acute myocardial infarction in COVID-19 are not yet available, myocardial infarction contributed to in-hospital mortality during previous severe acute respiratory syndrome/coronavirus epidemics. A recent study has also demonstrated that influenza and other respiratory viruses increase the incidence of acute myocardial infarction particularly in the first 7 days post-infection, suggesting that platelets may be directly involved in mediating an immune response but, when dysregulated, can also lead to thrombotic vascular occlusion.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=33151798&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641185/
dc.subjectthrombosis
dc.subjectCOVID-19
dc.subjectplatelets
dc.subjectinflammation
dc.subjectUMCCTS funding
dc.subjectBiological Factors
dc.subjectCardiovascular Diseases
dc.subjectCardiovascular System
dc.subjectHemic and Immune Systems
dc.subjectImmunology and Infectious Disease
dc.subjectInfectious Disease
dc.subjectMicrobiology
dc.subjectPathological Conditions, Signs and Symptoms
dc.subjectVirus Diseases
dc.titlePlatelets and COVID-19: Inflammation, Hyperactivation and Additional Questions
dc.typeEditorial
dc.source.journaltitleCirculation research
dc.source.volume127
dc.source.issue11
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/144
dc.identifier.contextkey20304128
html.description.abstract<p>The mechanisms underlining thrombosis in COVID-19 patients are not known and likely due to multiple processes including inflammation, oxygen demand injury, and plaque rupture triggered by the infection. Platelets mediate thrombotic vascular occlusion but are also increasingly recognized to have immunomodulatory activity. Several of our recent studies have characterized the role of viral infections in cardiac disease. Although robust data on the scope of acute myocardial infarction in COVID-19 are not yet available, myocardial infarction contributed to in-hospital mortality during previous severe acute respiratory syndrome/coronavirus epidemics. A recent study has also demonstrated that influenza and other respiratory viruses increase the incidence of acute myocardial infarction particularly in the first 7 days post-infection, suggesting that platelets may be directly involved in mediating an immune response but, when dysregulated, can also lead to thrombotic vascular occlusion.</p>
dc.identifier.submissionpathcovid19/144
dc.contributor.departmentDepartment of Medicine, Division of Cardiovascular Medicine
dc.source.pages1419-1421


This item appears in the following Collection(s)

Show simple item record